Last reviewed · How we verify
Phase II Trial of Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
IMGN853 is designed to inhibit cell division and cell growth of folate receptor 1 (FRα)-expressing tumor cells. The purpose of this study is to test the safety of IMGN853 and bevacizumab and see what effects (good and bad) that this combination treatment has on subjects with recurrent endometrial cancer.
Details
| Lead sponsor | University of Oklahoma |
|---|---|
| Phase | Phase 2 |
| Status | WITHDRAWN |
| Start date | 2019-05-31 |
| Completion | 2022-05 |
Conditions
- Endometrial Cancer
- Endometrial Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Clear Cell Adenocarcinoma
Interventions
- Mirvetuximab Soravtansine
- Bevacizumab
Primary outcomes
- Response rate of patients who remain progression free — 6 months
- Percentage of patients who remain progression free — 6 months
Countries
United States